BIO vs KNSA · rev $651.0M vs P/E 53, rev $677.6M
BIO (BIO) versus Kiniksa Pharmaceuticals Ltd (KNSA) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Kiniksa Pharmaceuticals Ltd (KNSA) is a drug manufacturers - specialty & generic company listed on US.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported KNSA revenue for 2025-12-31 was $677.6M. Net income was $59.0M. Revenue was up 60.1% from 2024-12-31 to 2025-12-31. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.
BIO currently screens at market cap $0. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.
Not investment advice. Open the BIO and KNSA stock pages for the full models.
Not investment advice.